{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:25:16Z","timestamp":1777353916429,"version":"3.51.4"},"reference-count":24,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2012]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; The management of cancer-related anorexia\/cachexia syndrome (CACS) is a great challenge in clinical practice. To date, practice guidelines for the prevention and treatment of CACS are lacking. The authors conducted a randomized study to confirm the effectiveness and safety of treatment of CACS utilizing megestrol acetate (MA) plus thalidomide. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; One hundred and two candidates with CACS were randomly assigned to two treatment groups (trial group and control group): the trial group received MA (160 mg po, bid) plus thalidomide (50 mg po, bid), while the control group received MA (160 mg po, bid) alone. Treatment duration was 8 weeks. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Analysis of the trial group demonstrated a significant increase from baseline in body weight (&lt;0.01), quality of life (p = 0.02), appetite (p = 0.01), and grip strength (p = 0.01), and a significant decrease in fatigue, Glasgow Prognostic Score (p = 0.05), Eastern Cooperative Oncology Group performance status (p = 0.03), IL-6 (p &lt; 0.01), and tumor necrosis factor-\u03b1 (p = 0.02). In contrast, in the control group, endpoints with a significant improvement from baseline included body weight (p &lt; 0.02) and appetite (p = 0.02). The mean changes in the endpoints from baseline in the trial group were significantly greater compared with the control group: in the primary endpoints, body weight (p = 0.05), fatigue (p &lt; 0.01) and quality of life (p = 0.01), and in the secondary endpoints, grip strength (p = 0.05), Glasgow Prognostic Score (p = 0.02), Eastern Cooperative Oncology Group performance status (p = 0.02), IL-6 (p &lt; 0.01) and tumor necrosis factor-\u03b1 (p = 0.01). Toxicity was found to be relatively negligible in both groups. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; A combination regimen of MA and thalidomide is more effective than MA alone in the treatment of CACS.<\/jats:p>","DOI":"10.1159\/000346446","type":"journal-article","created":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T08:15:10Z","timestamp":1360311310000},"page":"461-467","source":"Crossref","is-referenced-by-count":63,"title":["Clinical Studies on the Treatment of Cancer Cachexia with Megestrol Acetate plus Thalidomide"],"prefix":"10.1159","volume":"58","author":[{"given":"Hong-Sheng","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Zhu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui-Cui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ming","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2013,2,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.v17.i3.30"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3109\/07357900801944856"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000219435"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(04)03307-0"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008664.pub2"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.03.007"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-005-0830-7"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-10-133"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665108007131"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902960162"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.v9.i2.10"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.v17.i3.30"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2012.27.2.128"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2001.9680613"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.08.013"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000298821"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000321014"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00219-6"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.12.435"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004310.pub2"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.03.007"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.047563"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2011.10.005"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114512004527"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/346446","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/346446","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/346446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:46:19Z","timestamp":1745433979000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000346446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,4,1]]},"published-print":{"date-parts":[[2013,4,16]]}},"URL":"https:\/\/doi.org\/10.1159\/000346446","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}